Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. - Wikidata - wikimedia - TriplyDB

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

http://www.wikidata.org/entity/Q33345661

about

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.Effect of renal function on pemetrexed-induced haematotoxicity Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer.Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer.Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.Antioxidants and Other Micronutrients in Complementary Oncology.Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis.A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group The antifolates Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Revisiting cutaneous adverse reactions to pemetrexed Cancer chemotherapy: targeting folic acid synthesis.Leptomeningeal disease: current diagnostic and therapeutic strategies.Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

P2860

Q26745422-485848B3-F11D-4AF2-BCE4-88B6B58595B1 Q28200350-F93888B3-2078-40F8-B709-ABA5F23DC8E7 Q33372119-25735B49-7511-4F4D-BDC3-41D85A9D4955 Q33398764-82C8FB29-8879-4D50-9058-9A806F34DE44 Q33432955-81115A26-AAF3-4440-BE46-C8F732058738 Q33754141-03430D2A-6330-4D43-A542-FD454226E329 Q33781269-DFC81A0F-0A17-4ABE-A55C-380A2A997D7C Q33781843-B55D0BC5-5D3B-4816-8D8A-4E0EDE9C8F43 Q34091240-DD402785-21E3-4516-A27A-3C36F06856B8 Q34140158-5A277ED7-E10B-4A58-9319-F058050FBCB1 Q34218443-035CFB1F-C498-4EFC-A3C3-95AFAF39715F Q34378396-1DF4EA7A-34E9-4E33-B516-8ADFFAD48B77 Q34458042-09A9479B-BA8B-4FC8-8454-D87DD2FEFC42 Q34692326-21149F2B-1AE5-44FF-8909-875E4A5C439E Q35931270-30322E09-5C5E-45AE-AA46-18D64733FED9 Q36611359-4B5F3F5D-BECE-4461-B743-20C40EAAB105 Q36614004-46AF7FBA-0F57-414D-B295-B1806DD7CE6A Q36779095-62688A65-C675-41AB-9A2B-05828D4F7552 Q36822893-E03E5507-8536-4F32-96FE-C3166DD9DA17 Q37105343-48BA3BD8-3A7F-4A2A-8C54-206C3244AD01 Q37172835-484F717B-1753-422C-87C7-83C3B24E833E Q37183495-BE68ADE9-0269-48E8-8016-8119D168E6C8 Q37212223-6AD0BFE5-4A7A-4FC1-9B18-956E80C92F0D Q37220528-A09B7B65-A21F-4FB5-A8E8-A0F710E1B2DC Q37598057-68F2280A-867B-42CE-A20E-9624F92F976A Q38032280-B91365BA-3905-4960-A168-36F32DF7B347 Q42588769-0FD6575D-CBE9-4199-8428-722B9C805206 Q42700664-A5F52C99-31ED-44E5-8771-CD8204A4048B Q52562413-0C8AB7D9-0A4F-4826-96B7-3BC7313D89FC Q55432585-53BC4011-46F6-428A-AE7A-26CC865A0F89

P2860

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

http://www.wikidata.org/entity/Q33345661

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@ast

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@en

type

label

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@ast

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@en

prefLabel

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@ast

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@en

P1433

Q33345661-315E45A8-E47C-448D-ABC0-C480B710A2B6

P1476

Q33345661-6F56AD17-7420-4D7D-BE3B-4F8BA58DE30E

P2093

Q33345661-09835D96-103D-44BF-B4B2-6AF3A56B06B2

Q33345661-0C76AC8E-11B2-4945-B60B-1E11E9CED724

Q33345661-2DD62345-D208-4303-AD8F-C088E7F2D8AF

Q33345661-49921A40-9070-4DEA-ADE5-53602CAF3328

Q33345661-4FA65DC2-B5E7-4C09-A38B-089926176835

Q33345661-7F7A36BE-8512-4A32-ACDD-7B61E118DD83

Q33345661-BF15A7CA-DD7D-493A-9741-5D18A373371C

Q33345661-D7BF28D8-A096-418C-A7E3-2E22A31D864C

Q33345661-E4163D57-C18D-4E52-9DD6-FCA0DCF4E75A

Q33345661-FEE5F47B-08B2-4446-B67F-1F1D5458A7F5

P304

Q33345661-4D34AF1D-731D-48C0-B76C-AF1894190D04

P31

Q33345661-BDDFB01C-104A-4065-8789-D4C3ECF7F3E3

P433

Q33345661-28DA370B-6803-4B8E-8365-7CCF58F5973F

P478

Q33345661-466BC02F-191C-4186-A6BE-C460DF29C302

P577

Q33345661-0ED6363F-193C-4481-9169-4328D8C24480

P698

Q33345661-F66563D5-88A0-4F2F-A4E3-5775ADC727AC

P1433

Molecular Cancer Therapeutics

P1476

Homocysteine and methylmalonic ...... icity from pemetrexed therapy.

@en

P2093

A Hilary Calvert

http://www.w3.org/2001/XMLSchema#string

Clet Niyikiza

http://www.w3.org/2001/XMLSchema#string

David E Seitz

http://www.w3.org/2001/XMLSchema#string

Jackie M Walling

http://www.w3.org/2001/XMLSchema#string

James J Rusthoven

http://www.w3.org/2001/XMLSchema#string

Katrina Nelson

http://www.w3.org/2001/XMLSchema#string

Paolo Paoletti

http://www.w3.org/2001/XMLSchema#string

Robert H Allen

http://www.w3.org/2001/XMLSchema#string

Sally P Stabler

http://www.w3.org/2001/XMLSchema#string

Sharyn D Baker

http://www.w3.org/2001/XMLSchema#string

P304

545-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12479273

http://www.w3.org/2001/XMLSchema#string